Advertisement
Screener

OMNIAB, INC. (OABI) EBITDA

OMNIAB, INC. (OABI) EBITDA

  • 2026-06-30: Basis Reported; EBITDA (m); Operating income -$6.64M; Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA (m); Operating income -$7.83M; Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$8.06M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$13.48M*; Operating income -$18.14M; Depreciation and amortization $4.66M*.

Complete source-backed ebitda history.

Available history
2021-12-31 to 2025-12-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported(m)-$6.64M(m)$13.41M(m)$110.00K*$2.68M*(m)$9.59M(m)-$353.00K
2026-03-31Reported(m)-$7.83M(m)$14.43M(m)$167.00K-$4.91M(m)$9.64M(m)$442.00K
2025-12-31Reported-$8.06M(m)(m)(m)-96.22%(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$13.48M*-$18.14M$4.66M*$2.24M-602.28%*$182.00K*-$9.76M*(m)$10.38M(m)-$1.16M
2025-06-30Reported-$11.57M*-$16.22M$4.65M*$3.90M-296.90%*$165.00K*-$5.15M*(m)$10.86M(m)$119.00K
2025-03-31Reported-$14.1M(m)(m)(m)-339.46%$209.00K-$15.87M(m)$12.60M(m)-$106.00K
2024-12-31Reported-$8.27M(m)(m)(m)-76.58%(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$14.84M*-$19.76M$4.93M*$4.17M-355.63%*$152.00K*-$6.58M*(m)$13.32M(m)-$2.71M
2024-06-30Reported-$10.20M*-$16.30M$6.10M*$7.61M-134.02%*$751.00K*-$12.18M*(m)$13.94M(m)-$1.90M
2024-03-31Reported-$17.6M(m)(m)(m)-463.14%$926.00K-$17.03M(m)$14.55M(m)-$2.62M
2023-12-31Reported-$16.27M(m)(m)(m)-337.45%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$15.47M*-$20.32M$4.84M*$5.48M-282.47%*$490.00K*-$6.20M*(m)$13.87M(m)-$3.30M
2023-06-30Reported-$14.59M*-$19.45M$4.86M*$6.95M-209.98%*$813.00K*-$10.02M*(m)$14.13M(m)-$3.44M
2023-03-31Reported-$3.59M(m)(m)(m)-21.24%$234.00K$27.69M(m)$13.76M(m)-$1.03M
2022-12-31Reported$13.87M(m)(m)(m)39.24%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$10.41M*-$14.91M$4.50M*$6.91M-150.61%*$3.92M*-$4.23M*(m)$13.19M(m)-$2.31M
2022-06-30Reported-$8.08M*-$12.57M$4.49M*$7.20M-112.20%*$4.29M*-$3.85M*(m)$11.48M(m)-$2.29M
2022-03-31Reported-$3.79M(m)(m)(m)-39.33%$3.95M$11.64M(m)$10.77M(m)-$1.94M
2021-09-30Reported(m)-$170.58K(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-06-30Reported(m)-$2.19K(m)(m)(m)(m)(m)(m)(m)(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$47.22M(m)(m)(m)-252.95%$565.00K-$36.45M(m)$47.75M(m)-$1.51M
2024-12-31Reported-$50.92M(m)(m)(m)-192.94%$1.88M-$39.66M(m)$55.11M(m)-$9.38M
2023-12-31Reported-$49.92M(m)(m)(m)-146.12%$1.64M$2.35M(m)$56.52M(m)-$13.74M
2022-12-31Reported-$8.4M(m)(m)(m)-14.22%$17.17M-$3.59M(m)$48.36M(m)-$3.73M
2021-12-31Reported-$19.36M(m)(m)(m)-55.71%$4.07M-$5.67M(m)$39.23M(m)-$7.31M

Similar stocks

Stock NameCountryMarket CapPE Ratio
NRC HEALTH (NRC)United States$0.450B42.50
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14